SUPERNOVA: A Strategy of UltraProtective lung ventilation With Extracorporeal CO2 Removal for New-Onset moderate to seVere ARDS
Extracorporeal CO2(ECCO2R) removal devices (PALP, MAQUET; ILA-active, NOVALUNG; Hemolung, ALung) allowVT and plateau pressure reduction in patients with moderate ARDS. This study aimed to assess changes in pH/ PaO2 /PaCO2, Respiratory Rate and device CO2 clearance in the first 24 hours of ECCO2R following VT and plateau pressure reduction in patients with moderate ARDS. Safety variables during treatment were also analysed.
Feasibility and safety
3 devices (MAQUET, NOVALUNG, ALUNG)
Efficacy and safety of lower versus higher CO2 extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study. Thorax. 2019 Dec;74(12):1179-1181. doi: 10.1136/thoraxjnl-2019-213591. Epub 2019 Aug 13
Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Intensive Care Med. 2019 May;45(5):592-600. doi: 10.1007/s00134-019-05567-4. Epub 2019 Feb 21
- Study design: to prospectively collect data on 100 patients during usual care in 21 centers.
- Study devices: PALP, MAQUET; ILA-active, NOVALUNG; Hemolung, ALung. All devices are CE-marked in the European Union.
• Supernova steering committee
For more information, please contact email@example.com